Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice

Journal of Molecular and Cellular Cardiology

Volumn 39, Issue 3, 2005, Pages 443-452

  Burleigh, Michael E ^a   Babaev, Vladimir R ^b   Yancey, Patricia G ^b   Major, Amy S ^b   McCaleb, Jennifer L ^b   Oates, John A ^a,b   Morrow, Jason D ^a,b   Fazio, Sergio ^b   Linton, MacRae F ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Bone marrow transplantation; COX 2; COX 2 selective inhibitors; Cyclooxygenase; Cyclooxygenase inhibitors; Inflammation; Knockout mice; Pharmacology; Prostaglandins

Indexed keywords

APOLIPOPROTEIN E; CYCLOOXYGENASE 2; INDOMETACIN; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROGENESIS; ATHEROGENIC DIET; ATHEROSCLEROSIS; CELL TRANSPLANTATION; CONTROLLED STUDY; ELIMINATION REACTION; ENZYME INHIBITION; FEMALE; FETUS; GENE DELETION; HEMATOPOIETIC CELL; INFLAMMATION; LIVER CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST;

ANIMALS; AORTA; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CELLS, CULTURED; CHEMOKINE CCL2; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; IMMUNOHISTOCHEMISTRY; INDOMETHACIN; LACTONES; LIPOPOLYSACCHARIDES; LIVER TRANSPLANTATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITROBENZENES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONAMIDES; SULFONES; TRANSPLANTATION, HETEROLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23644460499     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2005.06.011     Document Type: Article

References (68)

1. R. Ross Atherosclerosis - an inflammatory disease N. Engl. J. Med. 340 1999 115 126
2. R. DuBois, S. Abramson, L. Crofford, R.A. Gupta, L. Simon, and L. Van De Putte Cyclooxygenase in biology and disease FASEB J. 12 1998 1063 1073
3. U. Schonbeck, G.K. Sukhova, P. Graber, S. Coulter, and P. Libby Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions Am. J. Pathol. 155 1999 1281 1291
4. M.E. Burleigh, V.R. Babaev, J.A. Oates, R.C. Harris, S. Gautam, and D. Riendeau Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice Circulation 105 2002 1816 1823
5. J.R. Vane, Y.S. Bakhle, and R.M. Botting Cyclooxygenase 1 and 2 Ann. Rev. Pharmacol. Toxicol. 38 1998 97 120
6. G.A. FitzGerald, and C. Patrono The Coxibs, selective inhibitors of cyclooxygenase-2 N. Engl. J. Med. 345 2001 433 442
7. Y. Cheng, S.C. Austin, B. Rocca, B.H. Koller, T.M. Coffman, and T. Grosser Role of prostacyclin in the cardiovascular response to thromboxane A2 Science 296 5567 2002 539 541
8. O.A. Belton, A. Duffy, S. Toomey, and D.J. Fitzgerald Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis Circulation 108 2003 3017 3023
9. C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, and B. Davis Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N. Engl. J. Med. 343 2000 1520 1528
10. D. Solomon, S. Schneeweiss, R. Glynn, Y. Kiyota, R. Levin, and H. Mogun Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults Circulation 109 2004 2068 2073
11. W.A. Ray, C.M. Stein, J.R. Daugherty, K. Hall, P.G. Arbogast, and M.R. Griffin COX-2 selective nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease Lancet 360 2002 1071 1073
12. A.S. Reicin, D. Shapiro, R.S. Sperling, E. Barr, and Q. Yu Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone) Am. J. Cardiol. 89 2002 204 209
13. M.A. Konstam, M.R. Weir, A. Reicin, D. Shapiro, R.S. Sperling, and E. Barr Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib Circulation 104 2001 2280 2288
14. W.B. White, G. Faich, J.S. Borer, and R.W. Makuch Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib Am. J. Cardiol. 92 2003 411 418
15. F. Silverstein, G. Faich, J. Goldstein, L. Simon, T. Pincus, and A. Whelton Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term Arthritis Safety Study J. Am. Med. Assoc. 284 2000 1247 1255
16. M.F. Linton, and S. Fazio Cyclooxygenase-2 and inflammation in atherosclerosis Curr. Opin. Pharmacol. 4 2 2004 116 123
17. C.D. Furberg, B.M. Psaty, and G.A. FitzGerald Parecoxib, valdecoxib, and cardiovascular risk Circulation 111 3 2005 249
18. R. Chenevard, D. Hurlimann, M. Bechir, F. Enseleit, L. Spieker, and M. Hermann Selective COX-2 inhibition improves endothelial function in coronary artery disease Circulation 107 3 2003 405 409
19. F. Cipollone, C. Prontera, B. Pini, M. Marini, M. Fazia, and D. De Cesare Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2-dependent plaque instability Circulation 104 8 2001 921 927
20. F. Cipollone, M. Fazia, A. Iezzi, M. Zucchelli, B. Pini, and D. De Cesare Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans Circulation 107 11 2003 1479 1485
21. F. Cipollone, E. Toniato, S. Martinotti, M. Fazia, A. Lezzi, and C. Cuccurullo A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke J. Am. Med. Assoc. 291 2004 2221 2228
22. D. Pratico, C. Tillmann, Z.B. Zhang, H. Li, and G.A. FitzGerald Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice Proc. Natl. Acad. Sci. USA 98 2001 3358 3363
23. E.D. Reis, M. Roque, H. Dansky, J.T. Fallon, J.J. Badimon, and C. Cordon-Cardo Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice Proc. Natl. Acad. Sci. USA 97 2000 12764 12769
24. F. Bea, E. Blessing, B.J. Bennett, C.C. Kuo, L.A. Campbell, and J. Kreuzer Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis Cardiovasc. Res. 60 2003 198 204
25. M. Olesen, E. Kwong, A. Meztli, F. Kontny, I. Seljeflot, and H. Arnesen No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice Scand. Cardiovasc. J. 36 2002 362 367
26. N. Futaki, S. Takahashi, M. Yokoyama, I. Arai, S. Higuchi, and S. Otomo NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro Prostaglandins 47 1994 55 59
27. L.J. Marnett, T.L. Wright, B.C. Crews, S.R. Tannenbaum, and J.D. Morrow Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric oxide synthase J. Biol. Chem. 275 2000 13427 13430
28. V.R. Babaev, S. Fazio, L.A. Gleaves, K.J. Carter, C.F. Semenkovich, and M.F. Linton Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo J. Clin. Invest. 103 1999 1697 1705
29. V.R. Babaev, M.B. Patel, C.F. Semenkovich, S. Fazio, and M.F. Linton Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice J. Biol. Chem. 275 2000 26293 26299
30. M.F. Linton, J.B. Atkinson, and S. Fazio Prevention of atherosclerosis in apoE-deficient mice by bone marrow transplantation Science 267 1995 1034 1037
31. S. Fazio, V. Babaev, A. Murray, A. Hasty, K. Carter, and L. Gleaves Increased atherosclerosis in C57BL/6 mice reconstituted with apolipoprotein E null macrophages Proc. Natl. Acad. Sci. USA 94 1997 4647 4652
32. S.K. Basu, J.L. Goldstein, R.G.W. Anderson, and M.S. Brown Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts Proc. Natl. Acad. Sci. USA 73 1976 3178 3182
33. P.G. Yancey, and W.G. Jerome Lysosomal cholesterol derived from mildly oxidized low density lipoprotein is resistant to efflux J. Lipid Res. 42 2001 317 327
34. -/- mice Brain Res. 825 1999 86 94
35. Y. Nakashima, A.S. Plump, E.W. Raines, J.L. Breslow, and R. Ross ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree Arterioscler. Thromb. 14 1994 133 140
36. R.L. Reddick, S.H. Zhang, and N. Maeda Atherosclerosis in mice lacking apoE. Evaluation of lesional development and progression Arterioscler. Thromb. 14 1994 141 147
37. C.H. Hennekens, M.L. Dyken, and V. Fuster Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association Circulation 96 1997 2751 2753
38. D. Mukherjee, S.E. Nissen, and E.J. Topol Risk of cardiovascular events associated with selective COX-2 inhibitors J. Am. Med. Assoc. 286 2001 954 959
39. D. Rott, J. Zhu, M.S. Burnett, Y.F. Zhou, A. Zalles-Ganley, and J. Ogunmakinwa Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice J. Am. Coll. Cardiol. 41 2003 1812 1819
40. B. Paigen, P. Holmes, D. Mitchell, and D. Albee Comparison of atherosclerotic lesions and HDL-lipid levels in male, females, and testosterone-treated female mice from strains C57BL/6, BALB/c and C3H Atherosclerosis 68 1987 215 221
41. E.S. Krul, N. Napawan, D.T. Butteiger, K. Hayes, L. Krause, and G.E. Freidrich Atherosclerosis is reduced in cholesterol-fed ApoE(-/-) mice administered an ASBT inhibitor or a selective COX-2 inhibitor. Abstract Arterioscler. Thromb. Vasc. Biol. 22 2002 409
42. K.M. Egan, M. Wang, M.B. Lucitt, A.M. Zukas, E. Pure, and J.A. Lawson Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism Circulation 111 3 2005 334 342
43. S. Eligini, S. Colli, F. Basso, L. Sironi, and E. Tremoli Oxidized low density lipoprotein suppresses expression of inducible cyclooxygenase in human macrophages Arterioscler. Thromb. Vasc. Biol. 19 1999 1719 1725
44. S.B. Joseph, A. Castrillo, B.A. Laffitte, D.J. Mangelsdorf, and P. Tontonoz Reciprocal regulation of inflammation and lipid metabolism by liver X receptors Nat. Med. 9 2003 213 219
45. X. Fu, J. Menke, Y. Chen, G. Zhou, K. MacNaul, and S. Wright 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells J. Biol. Chem. 276 2001 38378 38387
46. D. Kothapalli, I. Fuki, K. Ali, S. Stewart, L. Zhao, and R. Yahil Anti-mitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation J. Clin. Invest. 113 4 2004 609 618
47. J. Masferrer, B. Zweifel, and K. Seibert P N. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice J. Clin. Invest. 86 1990 1375 1379
48. J.Y. Lee, K.H. Sohn, S.H. Rhee, and D. Hwang Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through toll-like receptor 4 J. Biol. Chem. 276 20 2001 16683 16689
49. K. Takayama, G. Garcia-Cardena, G.K. Sukhova, J. Comander, M.A. Gimbrone Jr., and P. Libby Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor J. Biol. Chem. 277 2002 44147 44154
50. L. Liang, D. Hu, W. Liu, J.P. Williams, P. Okunieff, and I. Ding Celecoxib reduces skin damage after radiation: selective reduction of chemokine and receptor mRNA expression in irradiated skin but not in irradiated mammary tumor Am. J. Clin. Oncol. 26 4 2003 S114 S121
51. W. Peters, and I.F. Charo Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice Curr. Opin. Lipidol. 12 2 2001 175 180
52. K.S. Michelsen, M.H. Wong, P.K. Shah, W. Zhang, J. Yano, and T.M. Doherty Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice-deficient in apolipoprotein E. Proc Natl Acad Sci 101 2004 10679
53. R.M. Hinson, J.A. Williams, and E. Shacter Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2 Proc. Natl. Acad. Sci. USA 93 1996 4885 4890
54. G.E. Caughey, M. Pouliot, L.G. Cleland, and M.J. James Regulation of tumor necrosis factor-alpha and IL-1 beta synthesis by thromboxane A2 in nonadherent human monocytes J. Immunol. 158 1997 351 358
55. S. Jozefowski, M. Bobek, and J. Marcinkiewicz Exogenous but not endogenous prostanoids regulate cytokine secretion from murine bone marrow dendritic cells: EP2, DP, and IP but not EP1, EP3, and FP prostanoid receptors are involved Int. Immunopharm. 3 6 2003 865 878
56. V.E. Mack Strong, P.J. Mackrell, E.M. Concannon, J.R. Mestre, G.P. Smyth, and P.A. Schaefer NS-398 treatment after trauma modifies NF-kappaB activation and improves survival J. Surg. Res. 98 2001 40 46
57. C.J. Kim, J.C. Khoo, K. Gillotte-Taylor, A. Li, W. Palinski, and C.K. Glass Polymerase chain reaction-based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo: enhancement by tumor necrosis factor-alpha and interleukin-1 beta Arterioscler. Thromb. Vasc. Biol. 20 8 1976 1976 1982
58. S. Litovsky, M. Madjid, A. Zarrabi, S.W. Casscells, J.T. Willerson, and M. Naghavi Superparamagnetic iron oxide-based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo: enhancement by tissue necrosis factor-alpha, interleukin-1beta, and interferon-gamma Circulation 107 2003 1545 1549
59. -/- mice lacking tumor necrosis factor-alpha receptor p55 Atherosclerosis 176 2 2004 227 232
60. S.A. Schreyer, C.M. Vick, and R.C. LeBoeuf Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice J. Biol. Chem. 277 2002 12364 12368
61. U. Shankavaram, W. Lai, S. Netzel-Arnett, P. Mangan, J. Ardans, and N. Caterina Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin- dependent regulation and role in metalloproteinase-2 activation J. Biol. Chem. 276 2001 19027 19032
62. R.B. Wesley 2nd, X. Meng, and D. Godin Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro Arterioscler. Thromb. Vasc. Biol. 18 1998 432 440
63. E. Scandella, Y. Men, D.F. Legler, S. Gillessen, L. Prikler, and B. Ludewig CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2 Blood 103 2004 1595 1601
64. K. Kabashima, D. Sakata, M. Nagamachi, Y. Miyachi, K. Inaba, and S. Narumiya Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells Nat. Med. 9 2003 744 749
65. A. Yilmaz, C. Reiss, O. Tantawi, A. Weng, C. Stumpf, and D. Raaz HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis Atherosclerosis 172 2004 85 93
66. K.B. Pomerantz, A.C. Nicholson, and D.P. Hajjar Signal transduction in atherosclerosis: second messengers and regulation of cellular cholesterol trafficking Adv. Exp. Med. Biol. 369 1995 49 64
67. C.S. Baker, R.J. Hall, T.J. Evans, A. Pomerance, J. Maclouf, and C. Creminon Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages Arterioscler. Thromb. Vasc. Biol. 19 3 1999 646 655
68. F. Cipollone, B. Rocca, and C. Patrono Cyclooxygenase-2 expression and inhibition in atherothrombosis Arterioscler. Thromb. Vasc. Biol. 24 2 2004 246 255